JP2025521501A5 - - Google Patents

Info

Publication number
JP2025521501A5
JP2025521501A5 JP2024574565A JP2024574565A JP2025521501A5 JP 2025521501 A5 JP2025521501 A5 JP 2025521501A5 JP 2024574565 A JP2024574565 A JP 2024574565A JP 2024574565 A JP2024574565 A JP 2024574565A JP 2025521501 A5 JP2025521501 A5 JP 2025521501A5
Authority
JP
Japan
Prior art keywords
dose
approximately
administered
mosnetuzumab
lenalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024574565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521501A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/068804 external-priority patent/WO2023250367A1/en
Publication of JP2025521501A publication Critical patent/JP2025521501A/ja
Publication of JP2025521501A5 publication Critical patent/JP2025521501A5/ja
Pending legal-status Critical Current

Links

JP2024574565A 2022-06-22 2023-06-21 モスネツズマブおよびレナリドミドによる、以前に処置されていない濾胞性リンパ腫の処置のための方法 Pending JP2025521501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263354491P 2022-06-22 2022-06-22
US63/354,491 2022-06-22
PCT/US2023/068804 WO2023250367A1 (en) 2022-06-22 2023-06-21 Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide

Publications (2)

Publication Number Publication Date
JP2025521501A JP2025521501A (ja) 2025-07-10
JP2025521501A5 true JP2025521501A5 (cg-RX-API-DMAC7.html) 2025-07-29

Family

ID=87519897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024574565A Pending JP2025521501A (ja) 2022-06-22 2023-06-21 モスネツズマブおよびレナリドミドによる、以前に処置されていない濾胞性リンパ腫の処置のための方法

Country Status (11)

Country Link
US (1) US20240043553A1 (cg-RX-API-DMAC7.html)
EP (1) EP4543546A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025521501A (cg-RX-API-DMAC7.html)
KR (1) KR20250025678A (cg-RX-API-DMAC7.html)
CN (1) CN119546334A (cg-RX-API-DMAC7.html)
AU (1) AU2023286618A1 (cg-RX-API-DMAC7.html)
CA (1) CA3259327A1 (cg-RX-API-DMAC7.html)
IL (1) IL317679A (cg-RX-API-DMAC7.html)
MX (1) MX2024015750A (cg-RX-API-DMAC7.html)
TW (1) TWI881370B (cg-RX-API-DMAC7.html)
WO (1) WO2023250367A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006456A1 (en) * 2024-06-25 2026-01-02 Genentech, Inc. Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
IL301086A (en) * 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
WO2022098638A2 (en) * 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
JP7716473B2 (ja) * 2020-11-04 2025-07-31 ジェネンテック, インコーポレイテッド 抗cd20/抗cd3二重特異性抗体の皮下投薬
WO2026006456A1 (en) * 2024-06-25 2026-01-02 Genentech, Inc. Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide

Similar Documents

Publication Publication Date Title
JP2021527092A5 (cg-RX-API-DMAC7.html)
JP2023541432A5 (cg-RX-API-DMAC7.html)
JPS6143112A (ja) 精神性欲機能障害治療剤
JP2022509262A5 (cg-RX-API-DMAC7.html)
JP2024530189A5 (cg-RX-API-DMAC7.html)
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
JP2022544485A5 (cg-RX-API-DMAC7.html)
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2004525143A5 (cg-RX-API-DMAC7.html)
JP2017508737A5 (cg-RX-API-DMAC7.html)
JP2024540044A5 (cg-RX-API-DMAC7.html)
JP2023011549A5 (cg-RX-API-DMAC7.html)
JP2024531799A5 (cg-RX-API-DMAC7.html)
JP2022177119A5 (cg-RX-API-DMAC7.html)
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
EP2830605B1 (en) A combination medicament comprising phenylephrine and paracetamol
JP2023516753A5 (cg-RX-API-DMAC7.html)
CN103596565B (zh) 塞克硝唑在口腔感染治疗中的应用
JP2025511403A5 (cg-RX-API-DMAC7.html)
JP2025509613A5 (cg-RX-API-DMAC7.html)
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
TWI837197B (zh) 胺基甲酸酯化合物於預防、緩解或治療糖尿病周邊神經病變或化療誘發的周邊神經病變的用途
IL317679A (en) Methods for treating previously untreated follicular lymphoma with mosunatuzumab and nalididomide
WO2020207344A1 (zh) 匹莫齐特和甲氨蝶呤的药物组合及其应用